Neos Therapeutics, Inc. Form 4

July 28, 2015

## FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

Check this box if no longer subject to Section 16. Form 4 or Form 5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Last)

(City)

(Print or Type Responses)

1. Name and Address of Reporting Person \* Kearny Venture Assoicates II LLC

> (First) (Middle)

C/O NEOS THERAPEUTICS. INC., 2940 N. HWY 360

(Street)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol

Neos Therapeutics, Inc. [NEOS]

3. Date of Earliest Transaction (Month/Day/Year) 07/28/2015

Filed(Month/Day/Year)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check Applicable Line)

below)

Table I. Non-Devineting Committee Assuring Disposed of an Demoficially Commed

Director

Officer (give title

Issuer

Form filed by One Reporting Person X\_ Form filed by More than One Reporting

5. Relationship of Reporting Person(s) to

(Check all applicable)

10% Owner \_ Other (specify

**GRANT PRAIRIE, TX 75050** 

(City)	(State) (	Table Table	e I - Non-D	erivative Se	curiti	es Acqı	uired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactio Code (Instr. 8)	4. Securitie on(A) or Disp (Instr. 3, 4 a	osed o	of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	07/28/2015		C	180,217	A	( <u>1</u> )	180,217	I	See Footnote
Common Stock	07/28/2015		С	472,897	A	(1)	653,114	I	See Footnote (2)
Common Stock	07/28/2015		C	561,938	A	<u>(1)</u>	1,215,052	I	See Footnote

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. 5. Number of TransactionDerivative Code Securities (Instr. 8) Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series B Preferred Stock	<u>(1)</u>	07/28/2015		C	432,523	<u>(1)</u>	<u>(1)</u>	Common Stock	180,217
Series B-1 Preferred Stock	(1)	07/28/2015		С	1,134,954	<u>(1)</u>	<u>(1)</u>	Common Stock	472,897
Series C Preferred Stock	(1)	07/28/2015		C	1,348,655	<u>(1)</u>	<u>(1)</u>	Common Stock	561,938

# **Reporting Owners**

Reporting Owner Name / Address		Relationships					
	Director	10% Owner	Officer	Other			
Kearny Venture Assoicates II LLC C/O NEOS THERAPEUTICS, INC. 2940 N. HWY 360 GRANT PRAIRIE, TX 75050		X					
BURRILL LIFE SCIENES CAPITAL FUND III L P C/O NEOS THERAPEUTICS, INC. 2940 N. HWY 360 GRANT PRAIRIE, TX 75050		X					
Castelein Caley C/O NEOS THERAPEUTICS, INC. 2940 N. HWY 360 GRANT PRAIRIE, TX 75050		X					
Dalal Anupam C/O NEOS THERAPEUTICS, INC. 2940 N. HWY 360		X					

Reporting Owners 2

#### **GRANT PRAIRIE, TX 75050**

### **Signatures**

Kearny Venture Associates II, LLC, by: /s/ Caley Castelein, Managing Member				
**Signature of Reporting Person	Date			
Burrill Life Sciences Capital Fund III, L.P. by: its General Partner Kearny Venture Associates II, LLC, by: /s/ Caley Castelein, Managing Member				
**Signature of Reporting Person	Date			
/s/ Caley Castelein	07/28/2015			
**Signature of Reporting Person	Date			
/s/ Anupam Dalal	07/28/2015			
**Signature of Reporting Person	Date			

### **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Each share of the Issuer's Series B preferred stock, Series B-1 preferred stock and Series C preferred stock was automatically converted on a 2.4-for-1 basis into common stock immediately prior to the closing of the Issuer's initial public offering (prior to the Company's 2.4-for-1 reverse common stock split the preferred stock would have converted on a 1-for-1 basis pursuant to its terms). The shares of Series B preferred stock, Series B-1 preferred stock and Series C preferred stock had no expiration date.
- The security listed in column 1 is held directly by Burrill Life Sciences Capital Fund III, L.P. ("Burrill"). Kearny Venture Associates II,

  LLC ("KVA II"), is the General Partner of Burrill. Caley Castelein and Anupam Dalal are the managing members of KVA II and share both voting power and disposal power over the shares. Each Reporting Person disclaims beneficial ownership of the Securities, except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3